Haemonetics Reports 3Q 2026 Revenue of $357.76M and EPS of $1
The company’s second-quarter revenue, net income and operating income increased year over year, supported by volume growth and share gains in Plasma, MedSurg growth and other factors.
Haemonetics’ second-quarter revenue and net income increased year over year, driven by volume growth and share gains in Plasma and growth in MedSurg. Operating income also rose on favorable product mix, tariff refunds, continued movement toward higher-margin offerings and the absence of fair-value…